GW9508
Modify Date: 2024-01-09 14:55:26
GW9508 structure
|
Common Name | GW9508 | ||
|---|---|---|---|---|
| CAS Number | 885101-89-3 | Molecular Weight | 347.407 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 538.4±45.0 °C at 760 mmHg | |
| Molecular Formula | C22H21NO3 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 279.4±28.7 °C | |
| Symbol |
GHS05, GHS07, GHS09 |
Signal Word | Danger | |
Use of GW9508GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.IC50 value: 7.32 (pEC50) [1]Target: GPR40GW9508 is shown to be at least 100-fold selective against 220 other GPCRs, 60 kinases, 63 proteases, seven integrins and 20 nuclear receptors including PPARα, δ and γ (pEC50 4.0, 4 and 4.9, respectively). GW9508 produces a concentration-dependent increase in intracellular Ca2+ concentrations via GPR40 receptor activation and the GPR120 receptor. GW9508 is active as an agonist at both GPR40 and GPR120, it is approximately 100-fold selective for GPR40 with respect to GPR120. GW9508 produces a concentration-dependent increase (pEC50=6.14) in glucose-stimulated insulin secretion at high glucose levels (25 mM). GW9508 dose dependently stimulated insulin secretion in a glucose-sensitive manner in MIN6 cells. Furthermore, GW9508 is able to potentiate the KCl-mediated increase in insulin secretion in MIN6 cells. [1] GW9508 induced hyperpolarization and opening of KATP channels in rat β-cells. [2] GW9508 inhibits CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. GW9508 further suppresses expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-α and IFN-γ. GW9508 also inhibits CCL5 and CXCL10 production by normal human epidermal keratinocytes. [3] |
| Name | 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.IC50 value: 7.32 (pEC50) [1]Target: GPR40GW9508 is shown to be at least 100-fold selective against 220 other GPCRs, 60 kinases, 63 proteases, seven integrins and 20 nuclear receptors including PPARα, δ and γ (pEC50 4.0, 4 and 4.9, respectively). GW9508 produces a concentration-dependent increase in intracellular Ca2+ concentrations via GPR40 receptor activation and the GPR120 receptor. GW9508 is active as an agonist at both GPR40 and GPR120, it is approximately 100-fold selective for GPR40 with respect to GPR120. GW9508 produces a concentration-dependent increase (pEC50=6.14) in glucose-stimulated insulin secretion at high glucose levels (25 mM). GW9508 dose dependently stimulated insulin secretion in a glucose-sensitive manner in MIN6 cells. Furthermore, GW9508 is able to potentiate the KCl-mediated increase in insulin secretion in MIN6 cells. [1] GW9508 induced hyperpolarization and opening of KATP channels in rat β-cells. [2] GW9508 inhibits CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. GW9508 further suppresses expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-α and IFN-γ. GW9508 also inhibits CCL5 and CXCL10 production by normal human epidermal keratinocytes. [3] |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 538.4±45.0 °C at 760 mmHg |
| Molecular Formula | C22H21NO3 |
| Molecular Weight | 347.407 |
| Flash Point | 279.4±28.7 °C |
| Exact Mass | 347.152130 |
| PSA | 58.56000 |
| LogP | 4.74 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.641 |
| Storage condition | Store at RT |
| Water Solubility | DMSO: >20mg/mL |
| Symbol |
GHS05, GHS07, GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H315-H318-H335-H410 |
| Precautionary Statements | P261-P273-P280-P305 + P351 + P338-P501 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn,N |
| Risk Phrases | 22-37/38-41-50/53 |
| Safety Phrases | 26-39-60-61 |
| RIDADR | UN 3077 9 / PGIII |
|
~87%
GW9508 CAS#:885101-89-3 |
| Literature: PROMETIC BIOSCIENCES INC.; GAGNON, Lyne; GROUIX, Brigitte; GEERTS, Lilianne; LAURIN, Pierre; PENNEY, Christopher; ZACHARIE, Boulos Patent: WO2012/97427 A1, 2012 ; Location in patent: Page/Page column 41-42 ; |
|
~%
GW9508 CAS#:885101-89-3 |
| Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 17, # 6 p. 1584 - 1589 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |
|
Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.
J. Pharmacol. Exp. Ther. 352(2) , 380-94, (2015) Omega-3 fatty acids (n-3 FAs) are proposed to have many beneficial effects on human health. However, the mechanisms underlying their potential cancer preventative effects are unclear. G protein-couple... |
|
|
Short-chain fatty acid sensing in rat duodenum.
J. Physiol. 593(3) , 585-99, (2015) Luminal lipid in the duodenum modulates gastroduodenal functions via the release of gut hormones and mediators such as cholecystokinin and 5-HT. The effects of luminal short-chain fatty acids (SCFAs) ... |
|
|
Novel identification of the free fatty acid receptor FFAR1 that promotes contraction in airway smooth muscle.
Am. J. Physiol. Lung Cell. Mol. Physiol. 309 , L970-82, (2015) Obesity is one of the major risk factors for asthma. Previous studies have demonstrated that free fatty acid levels are elevated in the plasma of obese individuals. Medium- and long-chain free fatty a... |
| Benzenepropanoic acid, 4-[[(3-phenoxyphenyl)methyl]amino]- |
| 3-{4-[(3-Phenoxybenzyl)amino]phenyl}propanoic acid |
| gw9508 |
| GW-9508 |